Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 30;9(1):116.
doi: 10.1038/s41392-024-01827-y.

Two hits are better than one: rational dual strategy efficiently fights neuroblastoma

Jacques Zimmer  1 , Camille Rolin  2   3 , Markus Ollert  2   4
Affiliations

Two hits are better than one: rational dual strategy efficiently fights neuroblastoma

Jacques Zimmer et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The “double-hit” approach for the treatment of neuroblastoma. a Anaplastic lymphoma kinase (ALK) is an antigen frequently expressed at high levels on the surface of neuroblastoma cells. CAR-T cell therapy targeting ALK (ALK.CAR-T cells) demonstrate significant efficacy when this antigen is abundantly present. However, upon activation, ALK receptors are internalized and degraded, decreasing therefore their surface expression and altogether the efficacy of ALK.CAR-T cells. b The integration to the therapeutic strategy of ALK inhibitors (ALKi), capable of restoring high ALK surface expression, provides an opportunity to overcome this limitation. Consequently, the synergistic use of ALK inhibitors alongside ALK.CAR-T cell therapy emerges as a promising strategy to address the issue of antigenic variability in neuroblastoma cells. The figure was created with BioRender.com
See this image and copyright information in PMC

References

    1. Bergaggio E, et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell. 2023;41:2100–2116. doi: 10.1016/j.ccell.2023.11.004. - DOI - PMC - PubMed
    1. Ruella M. ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma. Cancer Cell. 2023;41:2016–2018. doi: 10.1016/j.ccell.2023.11.009. - DOI - PubMed
    1. Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat. Rev. Clin. Oncol. 2022;19:515–533. doi: 10.1038/s41571-022-00643-z. - DOI - PubMed
    1. Heitzeneder S, et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022;40:53.e9–69.e9. doi: 10.1016/j.ccell.2021.12.005. - DOI - PMC - PubMed
    1. Del Bufalo F, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 2023;388:1284–1295. doi: 10.1056/NEJMoa2210859. - DOI - PubMed

Publication types